Functioning islet cell tumor of the pancreas

1997 ◽  
Vol 38 (1) ◽  
pp. 135-138 ◽  
Author(s):  
M. J. Chung ◽  
B. I. Choi ◽  
J. K. Han ◽  
J. W. Chung ◽  
M. C. Han ◽  
...  
Keyword(s):  
Islet Cell ◽  
Late Phase ◽  
Islet Cell Tumor ◽  
Ct Scanning ◽  
Spiral Ct ◽  
Arterial Phase ◽  
Islet Cell Tumors ◽  
Contrast Enhanced ◽  
Projection Images ◽  
Detection And Localization

Purpose: The purpose of this study was to evaluate the usefulness of dynamic spiral CT, including multidimensional reformation, in the detection and localization of islet cell tumors of the pancreas. Material and Methods: Seven patients with histopathologically proven functioning islet cell tumors of the pancreas were studied with 2-phase contrast-enhanced spiral CT. Scanning of the arterial phase and late phase was started 30 s and 180 s, respectively, after injection of 100 ml of contrast medium at a rate of 3 ml/s. Results: Axial images in the arterial phase depicted the lesions in 5 patients, but in the late phase in only one patient. Multiplanar reformatted images of the arterial phase depicted the lesions in all 7 patients. Maximal intensity projection images demonstrated all lesions with information of their relationship to the vascular structure. Conclusion: Dynamic spiral CT with scanning during the arterial phase and retrospective multidimensional reformation is useful for preoperative detection and localization of small islet cell tumors of the pancreas.

Detection and Localization of Islet Cell Tumor of the Pancreas: Usefulness of the Arterial Dominant PhaseImages of Spiral CT

1996 ◽  
Vol 35 (4) ◽  
pp. 565
Author(s):  
Sam Soo Kim ◽  
Joon Koo Han ◽  
Byung Ihn Choi ◽  
Myoung Jin Chung ◽  
Sang Hyun Lee ◽  
...  
Keyword(s):  
Islet Cell ◽  
Islet Cell Tumor ◽  
Spiral Ct ◽  
Cell Tumor ◽  
Detection And Localization

scholarly journals Noninvasive Diagnosis of Hepatocellular Carcinoma on Sonazoid-Enhanced US: Value of the Kupffer Phase

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 141
Author(s):  
Hiroshi Takahashi ◽  
Katsutoshi Sugimoto ◽  
Naohisa Kamiyama ◽  
Kentaro Sakamaki ◽  
Tatsuya Kakegawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Diagnostic Performance ◽  
Late Phase ◽  
Imaging Feature ◽  
Arterial Phase ◽  
Liver Imaging ◽  
Noninvasive Diagnosis ◽  
Contrast Enhanced ◽  
Treatment Naïve ◽  
Hepatic Lesions

The aim of this study was to compare the diagnostic performance of Contrast-Enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) version 2017, which includes portal- and late-phase washout as a major imaging feature, with that of modified CEUS LI-RADS, which includes Kupffer-phase findings as a major imaging feature. Participants at risk of hepatocellular carcinoma (HCC) with treatment-naïve hepatic lesions (≥1 cm) were recruited and underwent Sonazoid-enhanced US. Arterial phase hyperenhancement (APHE), washout time, and echogenicity in the Kupffer phase were evaluated using both criteria. The diagnostic performance of both criteria was analyzed using the McNemar test. The evaluation was performed on 102 participants with 102 lesions (HCCs (n = 52), non-HCC malignancies (n = 36), and benign (n = 14)). Among 52 HCCs, non-rim APHE was observed in 92.3% (48 of 52). By 5 min, 73.1% (38 of 52) of HCCs showed mild washout, while by 10 min or in the Kupffer phase, 90.4% (47 of 52) of HCCs showed hypoenhancement. The sensitivity (67.3%; 35 of 52; 95% CI: 52.9%, 79.7%) of modified CEUS LI-RADS criteria was higher than that of CEUS LI-RADS criteria (51.9%; 27 of 52; 95% CI: 37.6%, 66.0%) (p = 0.0047). In conclusion, non-rim APHE with hypoenhancement in the Kupffer phase on Sonazoid-enhanced US is a feasible criterion for diagnosing HCC.

Tips and Tricks in Contrast-Enhanced Ultrasound (CEUS) for the Characterization and Detection of Liver Malignancies

2019 ◽  
Vol 40 (04) ◽  
pp. 404-424 ◽  
Author(s):  
Barbara Schellhaas ◽  
Deike Strobel
Keyword(s):  
Liver Cirrhosis ◽  
Contrast Enhancement ◽  
Late Phase ◽  
Therapeutic Monitoring ◽  
Arterial Phase ◽  
Focal Liver Lesions ◽  
Liver Lesions ◽  
Contrast Enhanced Ultrasound ◽  
Liver Malignancies ◽  
Contrast Enhanced

AbstractContrast-enhanced ultrasound (CEUS) has a high diagnostic accuracy in the assessment of focal liver lesions. Clinical context (presence of liver cirrhosis, history of other malignancy versus incidental finding) is crucial for the correct interpretation of CEUS findings. CEUS has to be preceded by structured anamnesis and clinical examination as well as accurate B-mode sonography. Metastases are the most common malignant liver lesions in a non-cirrhotic liver. According to their contrast enhancement in the arterial phase, metastases are categorized as hyper- and hypo-vascular metastases. A common feature of all metastatic lesions is washout of the contrast agent in the portal venous or late phase. In the context of liver cirrhosis, > 95 % of focal liver lesions are hepatocellular carcinomas (HCCs). HCCs typically show arterial phase hyperenhancement, followed by mild and gradual contrast washout occurring very late in the late phase. For intrahepatic cholangiocellular carcinoma (ICC), the pattern of contrast enhancement in the arterial phase can vary. However, all ICCs typically show early and pronounced washout. Other liver malignancies like lymphoma, angiosarcoma, epithelioid hemangioendothelioma and others are very rare. Except for the contrast washout seen in all liver malignancies, they do not display pathognomonic enhancement patterns upon CEUS. Thus, biopsy is indispensable for definite diagnosis of the tumor entity. Furthermore, CEUS is used for the detection of metastases and therapeutic monitoring after local ablative procedures. The examination procedure differs slightly depending on the specific indication (characterization, detection).

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With18F-Dihydroxy-Phenyl-Alanine and11C-5-Hydroxy-Tryptophan Positron Emission Tomography

2008 ◽  
Vol 26 (9) ◽  
pp. 1489-1495 ◽  
Author(s):  
Klaas P. Koopmans ◽  
Oliver C. Neels ◽  
Ido P. Kema ◽  
Philip H. Elsinga ◽  
Wim J. Sluiter ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Islet Cell ◽  
Islet Cell Tumor ◽  
Cell Tumor ◽  
Emission Tomography ◽  
Islet Cell Tumors ◽  
Pancreatic Islet Cell ◽  
Tumor Patients ◽  
Positron Emission ◽  
Pet Ct

PurposeTo evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers.Patients and MethodsCarcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent11C-5-hydroxytryptophan (11C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin (18F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information.ResultsIn carcinoid tumor patients, per-patient analysis showed sensitivities for11C-5-HTP PET,18F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for11C-5-HTP PET,11C-5-HTP PET/CT,18F-DOPA PET,18F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients18F-DOPA PET and11C-5-HTP PET detected more lesions than SRS (P < .001).11C-5-HTP PET was superior to18F-DOPA PET in islet cell tumors (P < .0001). In all cases, CT improved the sensitivity of the nuclear scans.Conclusion18F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and11C-5-HTP PET/CT in islet cell tumor patients.

scholarly journals Conspicuity of Malignant Pleural Mesothelioma in Contrast Enhanced MDCT – Arterial Phase or Late Phase?

2021 ◽  
Author(s):  
Lukas Luerken ◽  
Philipp Laurin Thurn ◽  
Florian Zeman ◽  
Christian Stroszczynski ◽  
Okka Wilkea Hamer
Keyword(s):  
Multiple Regression ◽  
Late Phase ◽  
Objective Analysis ◽  
Surrounding Tissue ◽  
Arterial Phase ◽  
Subjective Analysis ◽  
Portal Venous Phase ◽  
Contrast Enhanced ◽  
Venous Phase ◽  
Phase Scan

Abstract Background: To compare two different contrast phases intraindividually regarding conspicuity of MPM in chest MDCT. Methods: 28 patients with MPM were included in this retrospective study. For all patients, chest CT in standard arterial phase and abdominal CT in portal venous phase (scan delay ca. 70 s) was performed. First, subjective analysis of tumor conspicuity was done independently by two radiologists. Second, objective analysis was done by measuring Hounsfield units (HU) in tumor lesions and in the surrounding tissue in identical locations in both phases. Differences of absolute HUs in tumor lesions between phases and differences of contrast (HU in lesion – HU in surrounding tissue) between phases were determined. HU measurements were compared using paired t-test for related samples. Potential confounding effects by different technical and epidemiological parameters between phases were evaluated performing a multiple regression analysis.Results: Subjective analysis: In all 28 patients and for both readers conspicuity of MPM was better on late phase compared to arterial phase. Objective analysis: MPM showed a significantly higher absolute HU in late phase (75.4 vs 56.7 HU, p < 0.001). Contrast to surrounding tissue was also significantly higher in late phase (difference of contrast between phases 18.5 HU, SD 10.6 HU, p < 0.001). Multiple regression analysis revealed contrast phase and tube voltage to be the only significant independent predictors for tumor contrast.Conclusions: In contrast enhanced chest-MDCT for MPM late phase scanning seems to provide better conspicuity and higher contrast to surrounding tissue compared to standard arterial phase scans.

scholarly journals Size measurements of hepatocellular carcinoma: comparisons between contrast and two-dimensional ultrasound

2020 ◽  
Author(s):  
Fei Chen ◽  
Fei Wang ◽  
Mei Zhu ◽  
Si Sun ◽  
Zheng Liu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Late Phase ◽  
Size Difference ◽  
Arterial Phase ◽  
Two Dimensional ◽  
Test Results ◽  
Contrast Enhanced ◽  
2D Imaging ◽  
The Mean ◽  
Longitudinal Diameter

Abstract Background Ultrasound (US) imaging is known to underestimate tumor size in clinical. This study is aimed to compare the size measurements of hepatocellular carcinoma (HCC) in three US imaging modalities, i.e. two-dimensional (2D) imaging, the arterial phase (AP) and the late phase (LP) imaging of contrast-enhanced US (CEUS). Methods Fifty-eight clinically proved HCC patients were included. The 2D and CEUS imaging were performed with Siemens S2000, Philips iu22 and BioSound Twice. 2.5 mL of SonoVue® was injected for every CEUS performance. Two physicians measured the maximal longitudinal and the transverse diameters of the tumors in 2D, the AP and the LP of CEUS from one image section. The three measurements were compared by paired t test. Results The mean longitudinal diameter of HCC appeared to be maximal in the AP (4.73 ± 2.04 cm) of CEUS and minimal in the LP (3.98 ± 1.99 cm) of CEUS. The 2D diameter (4.26 ± 2.07 cm) was in the middle between two CEUS measurements. There were significant differences between any two measurements. Conclusion There is size difference between the three kinds of HCC measurement. It appeared to be maximal in the AP of CEUS and minimal in the LP. The 2D diameter was in the middle.

scholarly journals Size measurements of hepatocellular carcinoma: comparisons between contrast and two-dimensional ultrasound

2020 ◽  
Author(s):  
Fei Chen ◽  
Fei Wang ◽  
Si Sun ◽  
Mei Zhu ◽  
Zheng Liu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Late Phase ◽  
Size Difference ◽  
Arterial Phase ◽  
Two Dimensional ◽  
Test Results ◽  
Contrast Enhanced ◽  
2D Imaging ◽  
The Mean ◽  
Longitudinal Diameter

Abstract Background Ultrasound (US) imaging is known to underestimate tumor size in clinical. This study is aimed to compare the size measurements of hepatocellular carcinoma (HCC) in three US imaging modalities, i.e. two-dimensional (2D) imaging, the arterial phase (AP) and the late phase (LP) imaging of contrast-enhanced US (CEUS). Methods Fifty-eight clinically proved HCC patients were included. The 2D and CEUS imaging were performed with Siemens S2000, Philips iu22 and BioSound Twice. 2.5 mL of SonoVue® was injected for every CEUS performance. Two physicians measured the maximal longitudinal and the transverse diameters of the tumors in 2D, the AP and the LP of CEUS from one image section. The three measurements were compared by paired t test. Results The mean longitudinal diameter of HCC appeared to be maximal in the AP (4.73±2.04 cm) of CEUS and minimal in the LP (3.98±1.99 cm) of CEUS. The 2D diameter (4.26±2.07 cm) was in the middle between two CEUS measurements. There were significant differences between any two measurements. Conclusion There is size difference between the three kinds of HCC measurement. It appeared to be maximal in the AP of CEUS and minimal in the LP. The 2D diameter was in the middle.

scholarly journals Size measurements of hepatocellular carcinoma: comparisons between contrast and two-dimensional ultrasound

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Fei Chen ◽  
Fei Wang ◽  
Si Sun ◽  
Mei Zhu ◽  
Zheng Liu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Size ◽  
Late Phase ◽  
Size Difference ◽  
Arterial Phase ◽  
Two Dimensional ◽  
Contrast Enhanced ◽  
2D Imaging ◽  
The Mean ◽  
Longitudinal Diameter

Abstract Background Ultrasound (US) imaging is known to underestimate tumor size in clinical. This study is aimed to compare the size measurements of hepatocellular carcinoma (HCC) in three US imaging modalities, i.e. two-dimensional (2D) imaging, the arterial phase (AP) and the late phase (LP) imaging of contrast-enhanced US (CEUS). Methods Fifty-eight clinically proved HCC patients were included. The 2D and CEUS imaging were performed with Siemens S2000, Philips iu22 and BioSound Twice. 2.5 mL of SonoVue® was injected for every CEUS performance. Two physicians measured the maximal longitudinal and the transverse diameters of the tumors in 2D, the AP and the LP of CEUS from one image section. The three measurements were compared by paired t test. Results The mean longitudinal diameter of HCC appeared to be maximal in the AP (4.73 ± 2.04 cm) of CEUS and minimal in the LP (3.98 ± 1.99 cm) of CEUS. The 2D diameter (4.26 ± 2.07 cm) was in the middle between two CEUS measurements. There were significant differences between any two measurements. Conclusion There is size difference between the three kinds of HCC measurement. It appeared to be maximal in the AP of CEUS and minimal in the LP. The 2D diameter was in the middle.

scholarly journals Continuous Dynamic Registration of Microvascularization of Liver Tumors with Contrast-Enhanced Ultrasound

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Lukas Philipp Beyer ◽  
Benedikt Pregler ◽  
Isabel Wiesinger ◽  
Christian Stroszczynski ◽  
Philipp Wiggermann ◽  
...  
Keyword(s):  
Liver Tumors ◽  
Malignant Tumors ◽  
Regional Blood Flow ◽  
Late Phase ◽  
Diagnostic Value ◽  
Arterial Phase ◽  
Contrast Enhanced Ultrasound ◽  
Time To Peak ◽  
Contrast Enhanced ◽  
Significant Difference

Aim.To evaluate the diagnostic value of quantification of liver tumor microvascularization using contrast-enhanced ultrasound (CEUS) measured continuously from the arterial phase to the late phase (3 minutes).Material and Methods.We present a retrospective analysis of 20 patients with malignant (n=13) or benign (n=7) liver tumors. The tumors had histopathologically been proven or clearly identified using contrast-enhanced reference imaging with either 1.5 T MRI (liver specific contrast medium) or triphase CT and follow-up. CEUS was performed using a multifrequency transducer (1–5 MHz) and a bolus injection of 2.4 mL sulphur hexafluoride microbubbles. A retrospective perfusion analysis was performed to determine TTP (time-to-peak), RBV (regional blood volume), RBF (regional blood flow), and Peak.Results.Statistics revealed a significant difference (P<0.05) between benign and malignant tumors in the RBV, RBF, and Peak but not in TTP (P=0.07). Receiver operating curves (ROC) were generated for RBV, RBF, Peak, and TTP with estimated ROC areas of 0.97, 0.96, 0.98, and 0.76, respectively.Conclusion.RBV, RBF, and Peak continuously measured over a determined time period of 3 minutes could be of valuable support in differentiating malignant from benign liver tumors.

Sign in / Sign up

Export Citation Format

Share Document